• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

?
-

Resources for You

June 30, 2011 Approval Letter -Fluarix 2011/2012 Forumation

Our STN: BL 125127/472                

 
GlaxoSmithKline Biologicals
Attention: LaDonna Nugent, M.S.
2301 Renaissance Boulevard
Building 510, P.O. Box 61540
King of Prussia, PA 19406-2772
 
Dear Ms. Nugent:
 
We have approved your request to supplement your biologics license application for Influenza Virus Vaccine (Fluarix®), to include the 2011-2012 United States formulation.
 
Please submit all final printed labeling at the time of use and include implementation information on Form FDA 356h. Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.
 
We will include information contained in the above-referenced supplement in your biologics license application file.
 
 
Sincerely yours,
 
                                                                       
Jerry P. Weir, Ph.D.
Director
Division of Viral Products
Office of Vaccines
 Research and Review
Center for Biologics
 Evaluation and Research
 
 
Attachment: Approved Final Draft Labeling